Xenetic Biosciences (Xenetic Biosciences) EV-to-Revenue : -0.86 (As of May. 23, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Xenetic Biosciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Xenetic Biosciences's enterprise value is $-2.09 Mil. Xenetic Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $2.45 Mil. Therefore, Xenetic Biosciences's EV-to-Revenue for today is -0.86.

The historical rank and industry rank for Xenetic Biosciences's EV-to-Revenue or its related term are showing as below:

XBIO' s EV-to-Revenue Range Over the Past 10 Years
Min: -20946.71 Med: 2.49 Max: 53794.98
Current: -0.86

During the past 13 years, the highest EV-to-Revenue of Xenetic Biosciences was 53794.98. The lowest was -20946.71. And the median was 2.49.

XBIO's EV-to-Revenue is ranked better than
95.11% of 1042 companies
in the Biotechnology industry
Industry Median: 8.215 vs XBIO: -0.86

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-23), Xenetic Biosciences's stock price is $3.96. Xenetic Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.60. Therefore, Xenetic Biosciences's PS Ratio for today is 2.48.

Xenetic Biosciences EV-to-Revenue Historical Data

The historical data trend for Xenetic Biosciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenetic Biosciences EV-to-Revenue Chart

Xenetic Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

-95.93

14.45

-0.78

-5.14

-1.44

Xenetic Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															-3.03	-2.64	-0.96	-1.44	-0.82

Competitive Comparison of Xenetic Biosciences's EV-to-Revenue

For the Biotechnology subindustry, Xenetic Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xenetic Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's EV-to-Revenue falls into.

Xenetic Biosciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Xenetic Biosciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	-2.091	/	2.445
	=	-0.86

Xenetic Biosciences's current Enterprise Value is $-2.09 Mil.
Xenetic Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.45 Mil.

Xenetic Biosciences (NAS:XBIO) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Xenetic Biosciences's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	3.96	/	1.595
	=	2.48

Xenetic Biosciences's share price for today is $3.96.
Xenetic Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.60.

Xenetic Biosciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Xenetic Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Xenetic Biosciences (Xenetic Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenetic Biosciences Inc (NAS:XBIO) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

945 Concord Street, Framingham, MA, USA, 01701

Website

https://www.xeneticbio.com

Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

Executives

Grigory G. Borisenko	director	40 SPEEN STREET, SUITE 102, FRAMINGHAM MA 01701
Alexey Andreevich Vinogradov	director	C/O XENETIC BIOSCIENCES, INC., 40 SPEEN STREET, FRAMINGHAM MA 01701
Adam Logal	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
James Eric Callaway	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Dmitry Genkin	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
James F Parslow	officer: Chief Financial Officer	C/O XENETIC BIOSCIENCES, INC., 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Curtis Lockshin	officer: Chief Scientific Officer	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Benz Edward J. Jr	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Roger D. Kornberg	director	345 WALSH ROAD, ATHERTON CA 94027
Darlene M Deptula-hicks	director	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Jeffrey F Eisenberg	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Firdaus J. Dastoor	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Michael Scott Maguire	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Roman Knyazev	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Pharmsynthez Pjsc	10 percent owner	25 LITER KRASNOVO KURSANTA STREET, ST. PETERSBURG 1Z 197110